PARP1 and acute myeloid leukemia: This experimental study used reverse transcription-quantitative polymerase chain reaction (RT-qPCR) to quantify the expression levels of PARP1 and LIG3 at the transcript level in AML patients (n=78) and healthyindividuals (n=19).